X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SY-707 is a new generation of highly active ALK/FAK/IGF1R multi-target kinase inhibitor independently developed by Shouyao. It is currently in a critical Phase II/III clinical study and has received conditional Phase II approval in China.
Lead Product(s): SY-707
Therapeutic Area: Oncology Product Name: SY-707
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shouyao
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 03, 2021
Details:
Ascentage's lead drug, HQP1351, is developed to treat drug-resistant chronic myeloid leukemia. PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two parties will continue to advance and expand CDMO cooperation for current and future projects.
Lead Product(s): HQP1351
Therapeutic Area: Oncology Product Name: HQP1351
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ascentage Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
